SME Instrument funding awarded for  Finnish technology company Biomendex Oy

← Back to press releases

Biomendex Oy has developed a revolutionary synthetic bone graft substitute for bone regeneration. The invention, Adaptos™ is the first bioactive bone graft substitute that surgeons can cut, shape or squeeze into place, while eliminating bone harvesting in patients. Biomendex is changing the way bone voids are treated, by providing the bone graft substitutes that lead to better surgical outcomes, reduced operation time and risks, as well as lead to financial savings.

Horizon 2020 SME Instrument provides an excellent opportunity for small and medium sized companies to get financial support for product development and commercial uptake.
Applying for Horizon 2020 SME Instrument should be considered if your company:

• has developed a novel technological solution with a superior value proposition
• has already contracted the first customers and believes there is strong market demand for the solution
• has tested and validated a prototype proving the benefits of the technology.

The next SME Instrument cut-off date for Phase 2 projects is 09.10.2019. Invent Baltics OÜ provides initial consultancy regarding funding opportunities within the Horizon 2020 Research and Innovation programme free of charge.

← Back to press releases